Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
Background: In addition to reducing plasma lipids, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may produce numerous nonlipid-related pleiotropic effects. The purpose of this trial was to determine the efficacy of PCSK9 inhibitors alone in patients with isolated hypercholesterole...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/9/2542 |
| _version_ | 1797504140382830592 |
|---|---|
| author | Marcin Basiak Marcin Hachula Michal Kosowski Boguslaw Okopien |
| author_facet | Marcin Basiak Marcin Hachula Michal Kosowski Boguslaw Okopien |
| author_sort | Marcin Basiak |
| collection | DOAJ |
| description | Background: In addition to reducing plasma lipids, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may produce numerous nonlipid-related pleiotropic effects. The purpose of this trial was to determine the efficacy of PCSK9 inhibitors alone in patients with isolated hypercholesterolemia. Methods: The trial enrolled 21 individuals with isolated hypercholesterolemia and atherosclerosis who received alirocumab for 90 days (150 mg every two weeks). Lipids, glucose homeostasis factors, and hemostatic markers were measured in the plasma at baseline and after treatment. Results: The PCSK9 inhibitor administered to these patients reduced plasma levels/activity of fibrinogen (from 3.6 ± 0.5 to 2.9 ± 0.4 g/L, <i>p</i> < 0.01), factor VII (from 143.8 ± 16.7 to 114.5 ± 14.1%, <i>p</i> < 0.01) and plasminogen activator inhibitor-1 (PAI-1) (from 74.9 ± 13.9 to 52.8 ± 9.1 ng/mL, <i>p</i> < 0.001) without a significant reduction in von Willebrand factor levels, and it tended to prolong the partial thromboplastin and prothrombin times. Conclusion: Our findings indicate that treatment with PCSK9 inhibitors has a multipotential effect on fibrinolysis and coagulation in patients with isolated hypercholesterolemia and that this medication may have some future benefits in patients who are statin-intolerant or contraindicated to statin use. |
| first_indexed | 2024-03-10T04:01:24Z |
| format | Article |
| id | doaj.art-5c93f666a32949eaa983d73d5458c61d |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T04:01:24Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-5c93f666a32949eaa983d73d5458c61d2023-11-23T08:33:50ZengMDPI AGJournal of Clinical Medicine2077-03832022-05-01119254210.3390/jcm11092542Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated HypercholesterolemiaMarcin Basiak0Marcin Hachula1Michal Kosowski2Boguslaw Okopien3Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752 Katowice, PolandDepartment of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752 Katowice, PolandDepartment of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752 Katowice, PolandDepartment of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752 Katowice, PolandBackground: In addition to reducing plasma lipids, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may produce numerous nonlipid-related pleiotropic effects. The purpose of this trial was to determine the efficacy of PCSK9 inhibitors alone in patients with isolated hypercholesterolemia. Methods: The trial enrolled 21 individuals with isolated hypercholesterolemia and atherosclerosis who received alirocumab for 90 days (150 mg every two weeks). Lipids, glucose homeostasis factors, and hemostatic markers were measured in the plasma at baseline and after treatment. Results: The PCSK9 inhibitor administered to these patients reduced plasma levels/activity of fibrinogen (from 3.6 ± 0.5 to 2.9 ± 0.4 g/L, <i>p</i> < 0.01), factor VII (from 143.8 ± 16.7 to 114.5 ± 14.1%, <i>p</i> < 0.01) and plasminogen activator inhibitor-1 (PAI-1) (from 74.9 ± 13.9 to 52.8 ± 9.1 ng/mL, <i>p</i> < 0.001) without a significant reduction in von Willebrand factor levels, and it tended to prolong the partial thromboplastin and prothrombin times. Conclusion: Our findings indicate that treatment with PCSK9 inhibitors has a multipotential effect on fibrinolysis and coagulation in patients with isolated hypercholesterolemia and that this medication may have some future benefits in patients who are statin-intolerant or contraindicated to statin use.https://www.mdpi.com/2077-0383/11/9/2542PCSK9 inhibitorfactor VIIhypercholesterolemiaplasminogen activator inhibitor-1von Willebrand factorhemostasis |
| spellingShingle | Marcin Basiak Marcin Hachula Michal Kosowski Boguslaw Okopien Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia Journal of Clinical Medicine PCSK9 inhibitor factor VII hypercholesterolemia plasminogen activator inhibitor-1 von Willebrand factor hemostasis |
| title | Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia |
| title_full | Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia |
| title_fullStr | Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia |
| title_full_unstemmed | Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia |
| title_short | Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia |
| title_sort | effect of pcsk9 inhibitors on hemostasis in patients with isolated hypercholesterolemia |
| topic | PCSK9 inhibitor factor VII hypercholesterolemia plasminogen activator inhibitor-1 von Willebrand factor hemostasis |
| url | https://www.mdpi.com/2077-0383/11/9/2542 |
| work_keys_str_mv | AT marcinbasiak effectofpcsk9inhibitorsonhemostasisinpatientswithisolatedhypercholesterolemia AT marcinhachula effectofpcsk9inhibitorsonhemostasisinpatientswithisolatedhypercholesterolemia AT michalkosowski effectofpcsk9inhibitorsonhemostasisinpatientswithisolatedhypercholesterolemia AT boguslawokopien effectofpcsk9inhibitorsonhemostasisinpatientswithisolatedhypercholesterolemia |